These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8453001)

  • 1. [Can we decrease pharmacy costs?].
    Azagra Ledesma R
    Aten Primaria; 1993 Feb; 11(3):117-8. PubMed ID: 8453001
    [No Abstract]   [Full Text] [Related]  

  • 2. The economic value of companion diagnostics and stratified medicines.
    Blair ED; Stratton EK; Kaufmann M
    Expert Rev Mol Diagn; 2012 Nov; 12(8):791-4. PubMed ID: 23249194
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmaceutical industry financial performance.
    Goodman M
    Nat Rev Drug Discov; 2009 Dec; 8(12):927-8. PubMed ID: 19949398
    [No Abstract]   [Full Text] [Related]  

  • 4. Priced out of the UK market.
    Moran N
    Nat Biotechnol; 2008 Feb; 26(2):151-4. PubMed ID: 18259163
    [No Abstract]   [Full Text] [Related]  

  • 5. Market watch: pricing strategies for emerging markets.
    Lineberry N; Snyder E; Gunda S
    Nat Rev Drug Discov; 2011 Aug; 10(8):567. PubMed ID: 21804586
    [No Abstract]   [Full Text] [Related]  

  • 6. Validation--how much can the world afford? Are we getting value for money?
    Anisfeld MH
    J Pharm Sci Technol; 1994; 48(1):45-8. PubMed ID: 8004419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [An overlooked effect: synonyms reduce the price of original drug preparations].
    Gunnarsson B
    Lakartidningen; 1991 Jun; 88(24):2195. PubMed ID: 2056824
    [No Abstract]   [Full Text] [Related]  

  • 8. Costing drug development.
    Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358
    [No Abstract]   [Full Text] [Related]  

  • 9. Medicines pricing singled out.
    Buchanan E
    S Afr Med J; 2004 May; 94(5):334. PubMed ID: 15211941
    [No Abstract]   [Full Text] [Related]  

  • 10. [Medicoeconomic data on rare disease drugs: a move towards more transparency?].
    Schwebig A; Duguet C; Ferry A; Bougé C; Fagon JY; Bismuth C; Ramon J
    Presse Med; 2012 May; 41 Suppl 1():S57-64. PubMed ID: 22487716
    [No Abstract]   [Full Text] [Related]  

  • 11. [Analysis of the economic evaluation of drugs in primary care: concept, methodology and practical applications].
    Soto Alvarez J; Fernández Cano P
    Aten Primaria; 1997 Dec; 20(10):563-8. PubMed ID: 9494217
    [No Abstract]   [Full Text] [Related]  

  • 12. Corporate issues that will impact on infectious disease: the pharmaceutical industry.
    Cavanaugh JH
    Bull N Y Acad Med; 1987; 63(6):582-92. PubMed ID: 3118995
    [No Abstract]   [Full Text] [Related]  

  • 13. Expected net benefit of clinical pharmacy in intensive care medicine: a randomized interventional comparative trial with matched before-and-after groups.
    Claus BO; Robays H; Decruyenaere J; Annemans L
    J Eval Clin Pract; 2014 Dec; 20(6):1172-9. PubMed ID: 25470782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic conservatism.
    Griffin JP
    J R Coll Physicians Lond; 1993 Jul; 27(3):339. PubMed ID: 8031338
    [No Abstract]   [Full Text] [Related]  

  • 15. Sir Michael Rawlins on being NICE--and fair--about drug development and availability. Interview by Daniel Clarke.
    Rawlins SM
    Drug Discov Today; 2005 Mar; 10(6):383-6. PubMed ID: 15808816
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness data on biologics needed.
    Sheridan C; Katsnelson A
    Nat Biotechnol; 2005 Mar; 23(3):272-3. PubMed ID: 15765069
    [No Abstract]   [Full Text] [Related]  

  • 17. Value-based pricing: incentive for innovation or zero net benefit?
    Hughes DA
    Pharmacoeconomics; 2011 Sep; 29(9):731-5. PubMed ID: 21736392
    [No Abstract]   [Full Text] [Related]  

  • 18. Should NICE's threshold range for cost per QALY be raised? No.
    Raftery J
    BMJ; 2009 Jan; 338():b185. PubMed ID: 19171562
    [No Abstract]   [Full Text] [Related]  

  • 19. How NICE may be outflanked.
    Ferner RE; McDowell SE
    BMJ; 2006 May; 332(7552):1268-71. PubMed ID: 16735342
    [No Abstract]   [Full Text] [Related]  

  • 20. Should NICE's threshold range for cost per QALY be raised? Yes.
    Towse A
    BMJ; 2009 Jan; 338():b181. PubMed ID: 19171561
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.